Sign inJoin waitlistJoin the waitlist

William Sikov

Associate Professor of Medicine, Clinician Educator and Associate Professor of ObGyn · Women and Infants Hospital of Rhode Island

Credentials: · · · · · · ·

History

Women and Infants Hospital of Rhode Island
Present

1988–1991
UPMC
1985–1988
Internal Medicine
Tufts Medical Center
1982–1985
Yale Univ Sch of Med
1978–1982

Research

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete…
Journal of Clinical Oncology · 2015 · First of 17 authors · Corresponding · 774 citations
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised,…
The Lancet Oncology · 2018 · 622 citations
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
Journal of Clinical Oncology · 2005 · 325 citations

Lisa Carey
13 papers
Mehra Golshan
12 papers
Howard Safran
10 papers
William Symmans
10 papers
Norman Wolmark
9 papers
Charles Geyer
8 papers
CH
Clifford Hudis
8 papers
Eric Winer
8 papers
GS
George Somlo
8 papers
Hope Rugo
7 papers
JO
Joyce O'Shaughnessy
6 papers
Wallace Akerley
6 papers

Grants

Cancer and Leukemia Group b
National Cancer Institute · U10
Contact PI · $97.9K · Rhode Island Hospital
1979–2003

Clinical trials

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Principal investigator · Completed · Phase 2
William Sikov MD
2010–2013
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2009–2025
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Principal investigator · Completed · Phase 2
William Sikov MD
2008–2014
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Principal investigator · Completed · Phase 2
William Sikov MD
2008–2015